MA37998A1 - Anti-cd3 antibodies, bispecific antigen binding molecules that bind to cd3 and cd20, and their uses - Google Patents
Anti-cd3 antibodies, bispecific antigen binding molecules that bind to cd3 and cd20, and their usesInfo
- Publication number
- MA37998A1 MA37998A1 MA37998A MA37998A MA37998A1 MA 37998 A1 MA37998 A1 MA 37998A1 MA 37998 A MA37998 A MA 37998A MA 37998 A MA37998 A MA 37998A MA 37998 A1 MA37998 A1 MA 37998A1
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- bind
- binding molecules
- bispecific antigen
- human
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention concerne des anticorps qui se lient à cd3 et des procédés d'utilisation de ceux-ci. Selon certains modes de réalisation, les anticorps de l'invention se lient à cd3 humain à affinité élevée et induisent la prolifération de lymphocytes t humains. L'invention comprend des anticorps qui se lient à cd3 et induisent la mort à médiation par des lymphocytes t de cellules tumorales. Selon certains modes de réalisation, la présente invention concerne des molécules de liaison à un antigène bispécifiques, comprenant un premier domaine de liaison à un antigène qui se lie spécifiquement au cd3 humain, et une seconde molécule de liaison à un antigène qui se lie spécifiquement au cd20 humain. Dans certains modes de réalisation, les molécules de liaison à un antigène bispécifiques de la présente invention sont aptes à inhiber la croissance de tumeurs à cellules b exprimant cd20. Les anticorps et molécules de liaison à un antigène bispécifiques de l'invention sont utiles pour le traitement de maladies et de troubles dans lesquels une réponse immunitaire ciblée, régulée à la hausse ou induite, est souhaitée et/ou bénéfique thérapeutiquement. Par exemple, les anticorps de l'invention sont utiles pour le traitement de divers cancers, ainsi que d'autres maladies et troubles associés à cd20.The present invention relates to antibodies that bind to cd3 and methods of using the same. In some embodiments, the antibodies of the invention bind to high affinity human cd3 and induce proliferation of human t cells. The invention includes antibodies that bind to cd3 and induce tumor cell-mediated death of tumor cells. In some embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds to human cd3, and a second antigen-binding molecule that specifically binds to human cd20. In some embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of cd20 expressing b-cell tumors. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which a targeted, upregulated or induced immune response is desired and / or therapeutically beneficial. For example, the antibodies of the invention are useful for the treatment of various cancers, as well as other diseases and disorders associated with cd20.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261704029P | 2012-09-21 | 2012-09-21 | |
PCT/US2013/060511 WO2014047231A1 (en) | 2012-09-21 | 2013-09-19 | Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
MA37998A1 true MA37998A1 (en) | 2017-07-31 |
MA37998B2 MA37998B2 (en) | 2020-07-29 |
Family
ID=59745478
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA37998A MA37998B2 (en) | 2012-09-21 | 2013-09-19 | Anti-cd3 antibodies, bispecific antigen-binding molecules that bind to cd3 and cd20, and their uses |
MA41873A MA41873B2 (en) | 2012-09-21 | 2013-09-19 | Anti-cd3 antibodies, bispecific antigen-binding molecules which bind to cd3 and cd20, and uses thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA41873A MA41873B2 (en) | 2012-09-21 | 2013-09-19 | Anti-cd3 antibodies, bispecific antigen-binding molecules which bind to cd3 and cd20, and uses thereof |
Country Status (1)
Country | Link |
---|---|
MA (2) | MA37998B2 (en) |
-
2013
- 2013-09-19 MA MA37998A patent/MA37998B2/en unknown
- 2013-09-19 MA MA41873A patent/MA41873B2/en unknown
Also Published As
Publication number | Publication date |
---|---|
MA37998B2 (en) | 2020-07-29 |
MA41873B2 (en) | 2022-04-29 |
MA41873A1 (en) | 2018-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA42935B1 (en) | Optimized anti-cd3 bispecific antibodies and their uses | |
MA49043B1 (en) | STABLE ANTIBODY FORMULATION | |
EA201990781A9 (en) | ANTI-STEAP2 ANTIBODIES, CONJUGATES ANTIBODY MEDICINES AND BISSPECIFIC ANTIGEN BINDING MOLECULES THAT BIND STEAP2 AND CD3, AND THEIR APPLICATION | |
EP4309740A3 (en) | Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof | |
JOP20160154B1 (en) | Anti-psma antibodies, bispecific antigen-binding molecules that bind psma and cd3, and uses thereof | |
MA44312A (en) | ANTIBODIES AND THEIR METHODS OF USE | |
EA201691858A1 (en) | ANTIBODY COMPOSITIONS FOR TREATMENT OF TUMORS | |
MA42542B1 (en) | Molecules Binding to pd-1 and Corresponding Methods of Use | |
MA43327A1 (en) | Peptides and peptide combination for use in immunotherapy against non-small cell lung cancer and other cancers | |
MA43328A1 (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
MA44101A (en) | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST BREAST CANCER AND OTHER CANCERS | |
MA46022A (en) | NEW PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS | |
EA201490957A1 (en) | TREATMENT OF HEMATOLOGICAL MALIGNANT DISEASES WITH ANTI-CXCR4 ANTIBODY | |
MA40041A (en) | ANTI-GITR ANTIBODIES AND THEIR METHODS OF USE | |
MA43458A1 (en) | Novel peptides, peptide combinations and carriers for use in the immunotherapeutic treatment of various cancers | |
MA33402B1 (en) | COMPOSITIONS AND METHODS FOR TARGETING COMPLEMENT C3B PROTEIN BY ANTIBODIES | |
MX2020008445A (en) | Methods for treating cancer with anti-pd-1 antibodies. | |
MA33387B1 (en) | POLYPEPTIDES AND PROCESSING METHOD | |
MA37998A1 (en) | Anti-cd3 antibodies, bispecific antigen binding molecules that bind to cd3 and cd20, and their uses | |
MA42523B1 (en) | Anti-psma antibodies, bispecific antigen-binding molecules which bind psma and cd3 and uses thereof | |
MX2021008453A (en) | Formulations of antibodies that bind human cd137 and uses thereof. | |
MA39751B1 (en) | Antibody compositions for the treatment of tumors | |
MA46281B1 (en) | Anti-muc16 antibodies (mucin 16) | |
MA39202B1 (en) | Human antibodies against pd-l1 | |
EA202190314A1 (en) | BISPECIFIC ANTI-BCMA X ANTI-CD3 ANTIBODIES AND METHODS OF THEIR APPLICATION |